将患者偏好前瞻性整合到老年早期激素受体阳性乳腺癌辅助治疗决策中
研究纳入95例≥65岁I期激素受体阳性乳腺癌患者,在简易多学科门诊(s-MDC)中结合会诊前问卷评估决策偏好与治疗态度。结果显示辅助治疗选择包括无治疗16.8%、单用内分泌治疗16.8%、单用放疗20.0%、内分泌联合放疗45.3%。治疗决策主要由患者偏好、预期寿命和治疗倾向驱动,而非基线患者报告指标或肿瘤特征。
要点
- 老年早期HR+乳腺癌辅助治疗选择多样,患者偏好是决策核心驱动因素。
- 年龄较大、死亡风险较高和偏好决策自主与省略全部治疗或省略内分泌治疗相关。
- 肿瘤较大(T1b/T1c)患者更常接受内分泌联合放疗。
核心结论
- 在s-MDC模式下,治疗决策主要由患者偏好、预期寿命和治疗倾向驱动,而非基线患者报告指标或肿瘤特征。
研究设计与样本
- 所有患者完成决策自主偏好量表、医疗最大化-最小化量表和e-Prognosis 10年死亡风险估计。
- 回顾性审查人口学、临床变量和所选治疗,使用χ2检验、t检验和回归分析关联。
主要发现
- 95例患者中辅助治疗包括无治疗16.8%、单用内分泌治疗16.8%、单用放疗20.0%、内分泌联合放疗45.3%。
- 年龄较大、死亡风险较高和偏好决策自主与省略全部治疗或省略内分泌治疗相关。
- 「最小化者」倾向单用内分泌治疗,而「最大化者」常选择放疗或内分泌联合放疗。
- 基线患者报告数据及大多数临床病理因素均不能预测单用放疗。
- 唯一与选择相关的临床病理因素是肿瘤大小:较大(T1b/T1c)肿瘤患者更常接受内分泌联合放疗。
临床怎么用
- 建议在老年早期乳腺癌辅助治疗决策中整合患者价值观和偏好评估。
- 对于放弃内分泌治疗的患者,单用放疗是常见选择,支持进一步研究该策略。
局限性
- 样本量95例,来自单中心s-MDC设置,回顾性审查治疗选择。
- 基线患者报告数据和大多数临床病理因素未能预测单用放疗,提示存在未测量因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Guidelines for women aged ≥65 years with early-stage, hormone receptor-positive cancer allow for a range of adjuvant strategies following breast-conserving surgery. These include hormone therapy (HT) with or without radiation therapy (RT), RT alone if HT is not desired or feasible, or even no adjuvant therapy. Although these options offer flexibility, they can also create uncertainty. To address this, we implemented a simple multidisciplinary clinic (s-MDC) with same-day medical and radiation oncology consultations, alongside a previsit questionnaire assessing decision-making preferences and treatment attitudes. METHODS AND MATERIALS: We evaluated 95 patients aged ≥65 years with stage I, hormone receptor-positive breast cancer seen in the s-MDC from August 2020 to December 2023. All completed the Decision Autonomy Preference Scale, Medical Maximizing-Minimizing Scale, and e-Prognosis 10-year mortality risk estimates. We retrospectively reviewed demographics, clinical variables, and chosen treatments, examining associations using χ2 tests, t tests, and regressions. RESULTS: Among 95 patients, adjuvant treatments included no therapy (16.8%), HT alone (16.8%), RT alone (20.0%), and HT+RT (45.3%). Older age, higher mortality risk, and a preference for decision autonomy correlated with omission of all therapy or omission of HT. "Minimizers" favored HT alone, whereas "maximizers" often chose RT or HT+RT. Neither baseline patient-reported data nor most clinicopathologic factors predicted the use of RT alone. The only clinicopathologic factor associated with choice was tumor size: patients with larger (T1b/T1c) tumors more commonly received HT+RT. CONCLUSIONS: In this s-MDC setting, treatment decisions were driven largely by patient preferences, life expectancy, and treatment inclinations, rather than by baseline patient-reported measures or tumor features. These findings underscore the importance of integrating patient values into decision-making and support further research into RT-alone approaches for those forgoing HT, given the prevalence of this treatment choice.
引用
- Brown A, Alcorn S, Croog V, et al. Prospective Integration of Patient Preferences Into Adjuvant Therapy Decisions for Older Women With Early-Stage Hormone Receptor-Positive Breast Cancer Adjuvant Therapy Decisions in Breast Cancer. Pract Radiat Oncol. 2025. PMID: 41265561. doi:10.1016/j.prro.2025.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。